Publications by authors named "Hilde Azijn"

Claim this Profile
C
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Soumi Gupta, Johan Vingerhoets, Signe Fransen, Lotke Tambuyzer, Hilde Azijn

Antimicrob Agents Chemother· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
Lotke Tambuyzer, Johan Vingerhoets, Hilde Azijn, Bjorn Daems, Steven Nijs

AIDS Res Hum Retroviruses· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
Johan Vingerhoets, Hilde Azijn, Lotke Tambuyzer, Inge Dierynck, Sandra De Meyer

AIDS Res Hum Retroviruses· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.
Monika Peeters, Johan Vingerhoets, Lotke Tambuyzer, Hilde Azijn, Andrew Hill

AIDS· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Hilde Azijn, Ilse Tirry, Johan Vingerhoets, Marie-Pierre de Béthune, Guenter Kraus

Antimicrob Agents Chemother· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
Johan Vingerhoets, Lotke Tambuyzer, Hilde Azijn, Annemie Hoogstoel, Steven Nijs

AIDS· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Lotke Tambuyzer, Hilde Azijn, Laurence T Rimsky, Johan Vingerhoets, Pierre Lecocq

Antivir Ther· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.
Johan Vingerhoets, Hilde Azijn, Els Fransen, Inky De Baere, Liesbet Smeulders

J Virol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
Sandra De Meyer, Hilde Azijn, Dominique Surleraux, Dirk Jochmans, Abdellah Tahri

Antimicrob Agents Chemother· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
Dominique L N G Surleraux, Abdellah Tahri, Wim G Verschueren, Geert M E Pille, Herman A de Kock, Hilde Azijn

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
Jan Heeres, Marc R de Jonge, Lucien M H Koymans, Frits F D Daeyaert, Maarten Vinkers, Hilde Azijn

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Dominique L N G Surleraux, Herman A de Kock, Wim G Verschueren, Geert M E Pille, Louis J R Maes, Hilde Azijn

J Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.
Koen Andries, Hilde Azijn, Theo Thielemans, Donald Ludovici, Michael Kukla

Antimicrob Agents Chemother· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis